Mersana Therapeutics Reports Net Loss of $54.3 Million in Q2 2023

Mersana Therapeutics,(MRSN) a leading biopharmaceutica l company focused on developing innovative antibody-drug conjugates, has released its financial results for the second quarter of 2023. The company's financials indicate both a surge in collaboration revenue and a net loss for the period.

Net Loss in Q2 2023

Mersana Therapeutics faced a net loss of $54.3 million during the second quarter of 2023. This represents a challenging quarter in terms of profitability, with the company's financials showing a decline from previous periods.

Collaboration Revenue Soars to $10.7 Million